The AHA today expressed support for and urged all senators to support an amendment to the Labor, Health and Human Services and Education appropriations bill that would help address the out-of-control cost of prescription drugs. Offered by Sens. Dick Durbin (D-IL) and Chuck Grassley (R-IA), amendment #3787 would provide funding to enable HHS to require disclosure of drug pricing information in direct-to-consumer advertising. “DTC advertising has the potential to lead to overutilization of high-cost prescription drugs, including when lower-cost but equally effective options may be available,” AHA wrote in a letter to senators. “This is contributing to the unsustainable rate of growth in prescription drug spending, which is consuming a bigger portion of health care dollars each year. Requiring disclosure of drug pricing information in DTC advertising will meaningfully enhance drug pricing transparency and provide useful information for consumers as they engage in discussions with their providers about the best treatment options for their individual health care needs.”

Perspective
Public
From birth to death, from critical injuries to elective surgeries, from crisis and disaster to community food banks and health improvement initiatives —…
Blog
Public
As seen in the Wall Street Journal.Hospitals are the heart of communities across America for one fundamental reason: They support patients whenever, wherever…
Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…
Headline
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir,…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The White House yesterday launched TrumpRx, the direct-to-consumer platform that will serve as a hub to direct cash-paying consumers to drug manufacturers…